The market for weight loss products is still huge business

By: Trademagazin Date: 2024. 06. 17. 10:12

Over the years, the pharmaceutical industry has made many attempts to bring effective weight loss drugs to market, but these have often come with serious side effects and health risks. Amphetamine and its derivatives, such as dinitrophenol, which were once popular weight loss drugs, have been found to cause serious health problems, including neurological disorders and severe addiction.

Óriási a biznisz

Over the course of the last century, several active substances that are now banned were put on the market. In the 1930s, dinitrophenol was responsible for many deaths, while in the 1960s, rainbow pills containing amphetamine were responsible for many deaths. The withdrawal of Aminorex, launched in 1971, linked to high blood pressure cases, and the 1997 withdrawal of fenfluramine, which caused heart valve problems, are other examples of risky drug development practices.

The modern pharmaceutical industry has undergone significant changes in recent decades. According to WHO data, the level of global obesity has increased significantly, which poses new challenges to the pharmaceutical industry. Denmark’s Novo Nordisk and America’s Eli Lilly, as market leaders in weight loss drugs, offer innovative solutions such as GLP-1 agonists that help with weight loss, reduce appetite and speed up metabolism.

Novo Nordisk and Eli Lilly have made significant progress not only in weight loss, but also in the treatment of several other diseases, including diabetes, high blood pressure and heart disease. In addition, the effectiveness of GLP-1 agonists has been supported by several clinical trials, which show that these drugs can also reduce the risk of heart problems.